Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences insider Form 144 filing shows a planned sale of 80,258 shares of common stock through E*TRADE Financial on or after 02/02/2026, with an aggregate market value of $516,612.72. The filing notes 82,561,235 shares outstanding and a prior sale of 10,808 shares for $55,228.88 in the past three months.
Solid Biosciences insider David T. Howton has filed a notice of proposed stock sales under Rule 144. The filing covers 37,771 shares of common stock with an aggregate market value of $243,128.15, to be sold through E*TRADE Financial Corporation on NASDAQ around 02/02/2026.
The shares were acquired on 02/02/2026 via settlement of performance shares as compensation from the issuer. Over the prior three months, the same insider sold 4,932 common shares on 12/03/2025 for gross proceeds of $25,202.52.
A holder of SLDB common stock, Paul Herzich, has filed a notice of intent to sell up to 26,250 shares through E*TRADE on the NASDAQ, with an aggregate market value of $168,968.63. The issuer had 82,561,235 shares outstanding and the approximate sale date is February 2, 2026.
The shares to be sold were acquired on February 2, 2026 via settlement of performance shares from the issuer as compensation. Over the prior three months, Herzich sold 2,701 shares of common stock on December 3, 2025, generating gross proceeds of $13,802.11.
Solid Biosciences Inc. director Ilan Ganot reported routine equity compensation activity and a small tax-related share sale. On January 27, 2026, previously granted restricted stock units converted one-for-one into common stock, including 389 shares for his wife and 3,884 shares for him.
On January 28, 2026, 191 common shares indirectly held through his wife were sold at $6.59 per share to cover withholding taxes under a pre-established automatic sell-to-cover instruction and were not a discretionary trade. Following these events, he beneficially owns 95,255 shares individually, 4,042 shares jointly with Annie Ganot, 17,476 shares indirectly through his wife, and 19,394 shares through the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. CFO & Treasurer Kevin Tan reported routine equity transactions. On January 9, 2026, 11,250 restricted stock units (RSUs) converted into the same number of common shares at an exercise price of $0.00, reflecting scheduled vesting. On January 13, 2026, he sold 5,704 shares of common stock at $5.27 per share.
According to the disclosure, this sale was made solely to cover withholding taxes under an automatic “sell-to-cover” instruction adopted on August 15, 2024, and is described as not a discretionary trade by Mr. Tan. After these transactions, he directly holds 46,100 shares of common stock and 11,250 RSUs, with RSUs converting to common stock on a one-for-one basis and vesting in four equal annual installments from January 9, 2023.
A holder of SLDB common stock filed a notice of proposed sale on Form 144 covering 5,704 shares. These shares were acquired on 01/09/2026 through the settlement of vested restricted stock units from the issuer as compensation. The planned sale is indicated through E*TRADE Financial Corporation, with an approximate aggregate market value of 30,060.08 and an expected sale date of 01/13/2026 on the NASDAQ. The issuer reports 79,162,201 common shares outstanding, providing context for the relative size of this planned transaction.
Solid Biosciences director Ian F. Smith reported multiple equity award transactions. On 01/02/2026, he received a stock option for 18,012 shares of common stock at an exercise price of $5.45 per share and a grant of 13,761 restricted stock units (RSUs). These “Smith Equity Awards” vest in equal quarterly installments over 12 months from the grant date, with full acceleration if the Smith Agreement ends early or there is a change in control of the company.
On 01/06/2026, 4,573 previously granted RSUs fully vested and converted to 4,573 shares of common stock on a one‑for‑one basis. After these transactions, Smith directly held 131,264 shares of Solid Biosciences common stock, along with 18,012 options and 13,761 RSUs.
Solid Biosciences Inc. director Ilan Ganot reported equity transactions related to spouse-held awards and updated his share holdings. On January 3, 2026, 2,994 restricted stock units held by his wife converted into 2,994 shares of common stock, reflecting one-for-one conversion of these awards. On January 5, 2026, 1,053 shares of common stock associated with his wife were sold at $5.43 per share to cover withholding taxes after the vesting of previously granted restricted stock units, and the filing notes these sales do not represent a discretionary trade by Ms. Ganot.
Following these transactions, 17,278 shares of common stock are reported as indirectly owned through his wife. The filing also reports 95,413 shares of common stock held directly by Mr. Ganot (including shares held jointly with Annie Ganot) and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust, for which Adam and Annie Ganot serve as trustees.
Solid Biosciences (SLDB) director Ilan Ganot reported an open-market sale of common stock. On 11/10/2025, he sold 3,278 shares at a weighted average price of $4.12, executed in multiple trades within a $4.11–$4.12 range.
Following the transaction, he beneficially owned 95,412 shares directly. Additional indirect holdings reported include 14,839 shares held by his spouse and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences (SLDB) filed its Q3 2025 report, posting a net loss of $45.8 million, driven by higher R&D as clinical programs advanced. R&D was $38.9 million (vs. $27.3 million a year ago) and G&A was $9.2 million (vs. $7.9 million). Total operating expenses reached $48.1 million.
Liquidity remained strong with $236.1 million in cash, cash equivalents and available-for-sale securities as of September 30, 2025, and management indicates funding into the first half of 2027. The company strengthened its balance sheet earlier in the year via the February 2025 offering, yielding approximately $188.0 million in net proceeds and pre-funded warrants. Derivative liabilities tied to FA212 milestones were $6.6 million at quarter-end.
Pipeline updates included progress in SGT-003 (Duchenne), with interim data (as of September 29, 2025) described in the filing, ongoing screening for SGT-212 (FA), and IND/CTA clearances for SGT-501 (CPVT). Shares outstanding were 77,910,239 as of October 29, 2025.